Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Sarcoma: Page 3
FDA expands use of Qiagen lung cancer mutation test
By
LabPulse.com staff writers
Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in non-small cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.
June 1, 2021
Lucence, Waseda University partner on liquid biopsy test
By
LabPulse.com staff writers
Lucence believes the technology could be used in potential applications in early cancer detection and disease monitoring. Lucence plans to commercialize the liquid biopsy platform from its CLIA-licensed laboratory in Palo Alto.
March 23, 2021
Falling lung cancer rates drive cancer decline in U.S. over past 2 decades
By
Emily Hayes
The report found that in 2020, the cancer death rate was down by 31% compared with 1991, including a 2.4% decrease between 2017 and 2018, the ACS reported. The findings are in line with prior reports showing cancer death rates overall dropping in recent years.
January 11, 2021
FDA clears Foundation Medicine's liquid biopsy test
By
LabPulse.com staff writers
FoundationOne Liquid CDx can be used as a companion diagnostic for four cancer therapies, including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor for metastatic prostate cancer patients with BRCA1/2 mutations, and three epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer patients.
August 26, 2020
Cancer research groups partner for liquid biopsy trial
By
LabPulse.com staff writers
In a phase II, multicenter trial, researchers from the Canadian Cancer Trial Group will first investigate whether changes in circulating cell-free tumor DNA (ctDNA) can better predict immunotherapy response than radiographic assessments. They will then examine whether ctDNA patterns can guide treatment decisions for patients with non-small cell lung cancer.
July 29, 2020
Insurance coverage of liquid biopsies for cancer surges
By
Theresa Pablos
The study evaluated private insurance and Medicare coverage trends for tests that identify circulating tumor DNA (ctDNA), cell-free DNA fragments shed by tumors that contain information about the tumor's genetic properties. Clinicians can use the ctDNA data from liquid biopsies to make treatment decisions.
July 9, 2020
AI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancer
By
Emily Hayes
The method -- called cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) -- has been developed for blood and other kinds of liquid specimens. Testing screens for abnormal methylation, whereas liquid biopsy tests typically look for mutations, the researchers explained.
June 23, 2020
Seoul researchers tout Guardant360 clinical results
By
LabPulse.com staff writers
A team from Samsung Medical Center in Seoul found that the test offers "useful prognostic information beyond actionable biomarkers" for this patient population, Guardant said in a statement.
May 31, 2020
FDA approves Agilent assay for lung cancer
By
LabPulse.com staff writers
The test, called PD-L1 IHC 28-8 pharmDx, will help physicians identify patients with metastatic NSCLC who qualify for treatment with a dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both of which are manufactured by Bristol Myers Squibb.
May 17, 2020
Qiagen, NuProbe partner on next-generation sequencing liquid biopsy
By
LabPulse.com staff writers
The companies plan to integrate NuProbe's blocker displacement amplification technology with Qiagen's single primer extension technology to analyze DNA mutations with very low variant allele fractions and support noninvasive cancer genomic profiling. They also aim to develop NGS liquid biopsy oncology panels capable of achieving limit-of-detection standards more cost-effectively than other existing technologies.
March 16, 2020
MilliporeSigma to make Elypta liquid biopsy kits
By
LabPulse.com staff writers
Elypta's liquid biopsy kits analyze metabolites that are deregulated in several types of cancer, resulting in more accurate diagnoses, according to MilliporeSigma. The kits to be manufactured will use a biofluid sample to detect and analyze biological markers for cancer, enabling clinicians to diagnose patients and determine treatment options.
February 17, 2020
BioMarker Strategies advances immunotherapy test through SBIR grant
By
LabPulse.com staff writers
The contract runs for two years and covers use of the test for predicting response to treatments given alone or in combination to patients with non-small cell lung cancer (NSCLC). This represents the second phase of immunotherapy response test development for the NCI; in the first phase, BioMarker Strategies established proof of concept. Immunotherapies have revolutionized the treatment of several cancer types, but there is a strong need for better ways of identifying patients who benefit, as the objective response rates for PD-1/PD-L1 inhibitors are low, ranging from 10% to 30%.
January 6, 2020
Previous Page
Page 3 of 5
Next Page
